Three vaccines are on the verge of getting emergency use authorization and a total of 58 vaccines are in clinical trials on humans. The top three front-runners in the vaccine race, Pfizer and BioNTech, Moderna, and Oxford-AstraZeneca have published their vaccine efficacy rate, and all are much higher than this benchmark. The great news is, all these vaccines can be designed, developed, and tested much faster than traditional vaccines. That means we will need a total of 11 billion doses for inoculation. COVAX works with vaccine manufacturers and has access to a large portfolio of vaccines, which includes Moderna and AstraZeneca shots.

Source: Dhaka Tribune December 09, 2020 18:33 UTC